Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00512902
Other study ID # CST1571EUS210
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received August 6, 2007
Last updated October 24, 2014
Start date August 2007
Est. completion date December 2008

Study information

Verified date October 2014
Source University of California, Los Angeles
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of imatinib (gleevec) in subjects who have systemic sclerosis. Imatinib has been approved by the FDA for the treatment of newly diagnosed adult patients with CML (newly diagnosed adult patients and for the treatment of patients with an accelerated phase. Imatinib is also approved for the treatment of patients with a certain type of gastrointestinal cancer (called stromal tumors) but it has not been approved to treat systemic sclerosis. Imatinib works by interfering with an enzyme called tyrosine phosphatase resulting in suppression of the immune system. It als interferes with a protein called platelet derived growth factor receptor (PDGFr) that has been linked to increased fibrosis.


Description:

Systemic sclerosis is a rare, progressive disease that leads to hardening and tightening of the skin and connective tissues. It usually begins with a few dry patches of skin on the hands or face that begin getting thicker and harder. These patches then spread to other areas of the skin. In some cases, systemic sclerosis also affects the blood vessels an internal organs. Systemic sclerosis is one of a group of arthritic conditions called connective tissue disorders, a person's antibodies are directed against their own tissues.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 2008
Est. primary completion date November 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. All patients must fulfill the criteria for SSc by ACR criteria

2. Age of entry into the study = 18 yrs

3. FVC <85% of predicted.

4. Able to complete the 6MWT with a walking distance = 150 m

5. Patients must have dyspnea on exertion (grade = 2 on the Magnitude of Task component of the Mahler Modified Dyspnea Index).

6. SSc for = 10 years, with onset defined as the date of the first non-Raynaud manifestation typical of systemic sclerosis.

7. Patients may have limited (cutaneous thickening distal but not proximal to elbows and knees, with or without facial involvement) or diffuse (cutaneous thickening proximal to elbows and knees, often involving the chest or abdomen) cutaneous SSc (Medsger 1995).

8. Patients must show some evidence of alveolitis as defined by an HRCT of the lung which shows ground glass opacification as a radiographic marker of "alveolitis" or finely reticulated fibrosis or they must have alveolitis by BAL ( = 3% PMN's or = 2% eosinophils).

9. Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing.

10. Patients must be able to provide written voluntary informed consent.

Exclusion Criteria:

1. FVC = 50% of predicted or DLCO (corrected for Hgb but not for alveolar volume) = 35% of predicted (suggesting severe probably irreparable disease and/or significant pulmonary vascular involvement by SSc).

2. FEV1/FVC ratio <65% (to exclude significant airflow obstruction)

3. Clinically significant abnormalities on HRCT not attributable to SSc (e.g., lung mass, extensive scarring due to previous infection, etc.)

4. Clinically significant pulmonary hypertension documented on right heart catheterization (i.e., right ventricular systolic pressure of >50 mm Hg and/or mean PAP =30 mm Hg) pulmonary pressure or echocardiographic evidence of PAH (if echo cardiographic systolic pressure = 55 mmHg) or FVC/DLCO ratio >1.6 on pulmonary function testing

5. Persistent unexplained hematuria (>10 RBCs/hpf).

6. History of persistent leukopenia (white blood cell count <3500), neutropenia (absolute neutrophil count < 1500) or thrombocytopenia (platelet count <100,000).

7. Clinically significant anemia (<9.0 gm/dl)

8. Serum creatinine >ULN.

9. Pregnancy (documented by urine pregnancy test), breast feeding

10. If of child-bearing potential, failure regularly to employ a reliable means of contraception

11. Active infection of the lung or elsewhere, whose management would be compromised by Imatinib

12. Unreliability, drug abuse (including active alcoholism)

13. Any chronic, debilitating illness (other than SSc)

14. Smoking of cigars, pipes or cigarettes during the past 6 months

15. Baseline liver function tests (ALT or AST or bilirubin >1.5 x upper limit of normal

16. Previous use of prednisone > 10 mg per day. If on prednisone =10 mg/d, dose must have been stable for > 1 month.

17. All other medication with putative disease-modifying properties (e.g., D-penicillamine, cyclophosphamide, azathioprine, methotrexate, colchicine, Potaba) must be discontinued 1 month prior to beginning study medication.

18. Patient is < 5 years since she/he had a primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed except after consultation with the PI.

19. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)

20. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).

21. Patient has known chronic liver disease (i.e., chronic active hepatitis and cirrhosis).

22. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.

23. Use of contraindicated medications at baseline.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Imatinib
All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
Imatinib
Up to 600 mg QD PO for up to 1 year.

Locations

Country Name City State
United States UCLA David Geffen School of Medicine, Division of Rheumatology Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
University of California, Los Angeles Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (1)

Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, Assassi S, Saggar R, Singh RR, Furst DE. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung diseas — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment-related Adverse Events Treatment-related adverse events requiring discontinuation. Baseline vs. Endpoint (1 year) Yes
Secondary Change in FVC (Forced Vital Capacity) Measures the amount of air breathed out as a percent of predicted. Baseline vs. Endpoint (1 year) No
Secondary Change in TLC (Total Lung Capacity) No measures of dispersion was available for TLC as data were lost. This describes the total lung capacity as a percent of predicted. Baseline vs. Endpoint (1 year) No
Secondary Change in DLco DLCO (diffusing capacity or transfer factor of the lung for carbon monoxide (CO)) is the extent to which oxygen passes from the air sacs of the lungs into the blood. Commonly, it refers to the test used to determine this parameter. Baseline vs. Endpoint (1 year) No
Secondary Change in Modified Rodnan Skin Score (MRSS) No measures of dispersion was available as data were lost. The range of this measure is 0 to 51 and measures the extent of skin thickening with higher numbers representing thickening. Baseline vs. Endpoint No
See also
  Status Clinical Trial Phase
Completed NCT03274076 - Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Phase 1/Phase 2
Completed NCT04300426 - Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue) Phase 2
Recruiting NCT06058091 - RY_SW01 Cell Injection Therapy in Systemic Sclerosis Phase 1/Phase 2
Recruiting NCT04356755 - Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma. Phase 2
Suspended NCT06210945 - Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis Phase 2
Not yet recruiting NCT05947682 - Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis N/A
Not yet recruiting NCT04303208 - Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis N/A
Not yet recruiting NCT05177380 - Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis N/A
Recruiting NCT02551042 - CSL Behring Sclero XIII Phase 2
Terminated NCT02246348 - Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) N/A
Terminated NCT02243111 - Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound N/A
Completed NCT01933334 - Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) Phase 2
Completed NCT01468792 - Hemodynamic Changes in Connective Tissue Disease N/A
Terminated NCT00848107 - Open-Label Study of Oral Treprostinil in Digital Ulcers Phase 2
Completed NCT00984932 - Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension Phase 3
Completed NCT00074568 - Scleroderma Registry
Not yet recruiting NCT06412614 - Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
Terminated NCT00622687 - Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis Phase 2
Recruiting NCT04464434 - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Phase 4
Recruiting NCT04246528 - SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF) N/A